MTOR and kidney disorder: Rapamycin, an mTOR pathway inhibitor, has been investigated for treating various kidney diseases, but it has been mainly restricted to kidney transplantation (43–45) and tuberous sclerosis disorders (46) due to its potential nephrotoxicity (13).